BioXcel Therapeutics to announce phase 3 trial results for agitation treatment
Spero Therapeutics , Inc. (NASDAQ:SPRO) recently reported insider transactions by its CEO and President, Shukla Sath. On February 5, 2025, Sath sold a total of 155,333 shares, valued at approximately $121,159, with each share priced at $0.78. According to InvestingPro data, the stock is currently trading below its Fair Value, despite showing strong financial health with a current ratio of 2.68x and more cash than debt on its balance sheet. The sales were made to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) granted in previous years. Following these transactions, Sath holds 1,736,883 shares directly. While the stock has declined 30.9% over the past six months, InvestingPro analysis reveals that two analysts have revised their earnings upwards for the upcoming period. Discover more insights and 8 additional ProTips by accessing the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Spero Therapeutics has made interim leadership changes amid a Securities and Exchange Commission (SEC) inquiry. Esther Rajavelu has been appointed as Interim President and CEO, with Frank Thomas as Chairman of the Board. Concurrently, the company reported progress on its Phase 3 PIVOT-PO trial for Tebipenem HBr, a treatment for complicated urinary tract infections, with over 60% enrollment and full enrollment expected by the second half of 2025.
H.C. Wainwright has reiterated its Buy rating on Spero Therapeutics, highlighting the company’s progress in its Phase 3 trial for Tebipenem HBr. The firm expressed confidence in the timeline of the PIVOT-PO program, anticipating top-line results could become available in early 2026.
On the other hand, TD Cowen has downgraded Spero Therapeutics from Buy to Hold due to uncertainties regarding the timing of upcoming catalysts. This follows the discontinuation of Spero’s Phase 2 program for a drug candidate aimed at treating nontuberculous mycobacterial infections. Despite this, Spero Therapeutics continues to work on other projects, including a Phase 2 trial for a drug known as ’206, targeting hospital-acquired and ventilator-associated bacterial pneumonia.
These are the recent developments for Spero Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.